Drilon et al. conducted a prospective phase 2 trial in patients with RET-rearranged lung cancers, and found that the overall response rate (ORR) was 28% [95% CI 12–49%], but 73% of the patients required dose reduction due to drug-related adverse events10. The gene discussed is RET; the disease is lung carcinoma.